Gilead Sciences, Inc. (GILD)
Health Care · Biotechnology · US stock · S&P 500 component
$157.19
▲ +3.62 (2.36%)
Fair valueOvervalued
$112 −28.9% to fair value
$56fair band $95–$136$168
Day's range
$153.00 – $157.42
52-week range
$114.02 – $160.51
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that researches, develops and commercialises medicines. Its products are mainly known for treating HIV, and it also offers treatments for hepatitis, liver disease, cancer and other serious conditions, including cell therapy through its Kite unit. Its customers are wholesalers, pharmacies and healthcare providers who supply patients, along with government health programmes in many countries.
Gilead earns revenue from prescription medicines, with a large portion coming from antiviral drugs. Over the last twelve months revenue was $30.5 billion, growing at 2.6% a year across the last three years. The operating margin is -8.2%, which means the business recorded an operating loss, and the return on the capital invested in it is -6%. The company pays a dividend with a yield of 2.1%. On the site's X-Ray Score it receives 37 out of 100.
Price chart
52-wk range $114.02 – $160.51Volume 6,210,290Daily, split-adjusted
Vitals
Market cap$195.4B
52-week range$114.02 – $160.51
Volume (last day)6,210,290
P/E (TTM)–
EBIT / EV yield-1.1%
Free-cash-flow yield6.6%
Dividend yield2.1%
Revenue (TTM)$30.5B
Net income (TTM)−$3.2B
Operating margin-8.2%
Return on capital-5.7%
Debt incl. leases$26.2B
Cash & securities$3.2B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$112middle half of models $91 – $137
Overvalued
−28.9% to fair value
Average of the 7 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is Medium, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.
Price $157
Undervalued < $95Fair $95 – $136Overvalued > $136
P/B multiple
$94
P/S multiple
$138
EV/revenue multiple
$143
10-year DCF, revenue exit
$75
5-year DCF, revenue exit
$109
Dividend discount, stable
$89
Dividend discount, multi-stage
$135
Earnings power value · not used
$17
A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data
Valuation
Weak
26/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield-1.1%
Free-cash-flow yield6.6%
Fair value vs price0.7×
Growth
Weak
45/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)2.6%
EPS growth (3y)23.0%
Growth consistency90%
Profitability
Weak
38/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital-5.7%
Operating margin-8.2%
Gross profitability49.1%
Financial health
Weak
38/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score8 / 9
Interest cover-2.5×
Dividends
Weak
50/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield2.1%
Dividends vs free cash flow31%
Dividend growth2.6%
Quarterly results: last 6 quarters
-0.3%
Mar '25
+1.8%
Jun '25
+3.0%
Sep '25
+4.7%
Dec '25
+4.4%
Mar '26
+10.2%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $7.8B, diluted EPS $-8.45.
Compare with peers
INCY Incyte Corp80 VRTX Vertex Pharmaceuticals...50 AMGN Amgen Inc48 REGN Regeneron Pharmaceutic...47Other Biotechnology companies by X-Ray Score.
SWOT analysis: Gilead Sciences, Inc.
Strengthsinside the company
- Earnings per share have compounded at 23.0% a year over three years.
- Free cash flow equals 6.6% of the market value, which funds dividends, buybacks or debt paydown.
- Passes 8 of the 9 Piotroski tests, which points to improving profitability, funding and efficiency.
Weaknessesinside the company
- Return on invested capital is only -5.7% (median 17.7% for industry peers), so the business earns little above its cost of capital.
- Operating margin of -8.2% is thin against 26.2% for industry peers.
- Altman Z-score of 0.5 is in the zone linked with financial distress in past studies.
Opportunitiesvaluation and setting
- Dividends use only 31% of free cash flow, which leaves room to raise them.
- Price momentum is strong on the weekly and monthly signals (trends can reverse).
Threatsvaluation and setting
- The price is 29% above our fair value estimate, so there is little room for disappointment.
Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.
Compare GILD with peers and sector
Medians of 7 Biotechnology peers and of 59 Health Care stocks in our universe.
Largest peers (X-Ray Score): ABBV 41, AMGN 48, VRTX 50, REGN 47, MRNA 12, BIIB 44.
| Metric | GILD | Peers | Sector |
|---|---|---|---|
| X-Ray Score (out of 100) | 37 | 47 | 49 |
| Valuation | 26 | 36 | 55 |
| Growth | 45 | 35 | 48 |
| Profitability | 38 | 55 | 51 |
| Financial health | 38 | 55 | 48 |
| Dividends | 50 | 52 | 52 |
Sector leaders: highest X-Ray Score in Health Care
GILD ranks #50 of 60 in Health Care and #7 of 8 in Biotechnology by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.
Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.
Factor ratings for GILD
Each factor is rated by where GILD stands among the 60 Health Care stocks in our universe.
Rating against the sector
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
Against its own history
The last columns set today's figure against the company's own median of its last five financial years:
▲ Betterbetter than its usual level
▼ Worseworse than its usual level
≈ In linewithin its usual range
For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.
In total: 6 Good · 3 Average · 10 Bad of 19
Growth: 1 · 0 · 2
Profitability: 1 · 0 · 4
Financial strength: 1 · 0 · 2
Valuation: 1 · 0 · 2
Cash flow: 2 · 1 · 0
Efficiency: 0 · 2 · 0
| Factor | GILD | Rating | Sector median | Own 5-year median | Against own history |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth, 3 years a year | +2.6% | Bad beats 33% | +5.5% | – | – |
| Revenue growth, last year | +2.4% | Bad beats 23% | +7.1% | +2.4% | ≈ In line |
| EPS growth, 3 years a year | +23.0% | Good beats 81% | +5.0% | – | – |
| Profitability | |||||
| Gross margin | 79.6% | Good beats 89% | 65.0% | 78.3% | ≈ In line |
| Operating margin | -8.2% | Bad beats 3% | 16.4% | 28.0% | ▼ Worse |
| Net margin | -10.6% | Bad beats 3% | 11.1% | 20.9% | ▼ Worse |
| Return on invested capital | -5.7% | Bad beats 4% | 12.2% | – | – |
| Return on equity | -27.4% | Bad beats 3% | 13.7% | 24.8% | ▼ Worse |
| Financial strength | |||||
| Interest cover | -2.5x | Bad beats 3% | 9.4x | 8.1x | ▼ Worse |
| Current ratio | 1.27 | Bad beats 33% | 1.52 | 1.43 | ▼ Worse |
| Piotroski F-score | 8 / 9 | Good beats 85% | 6 / 9 | – | – |
| Valuation | |||||
| Price / book | 16.5x | Bad beats 10% | 3.7x | 5.1x | ▼ Worse |
| Price / sales | 6.4x | Bad beats 29% | 3.7x | 4.0x | ▼ Worse |
| Free cash flow yield | 6.6% | Good beats 80% | 4.4% | 7.7% | ▼ Worse |
| Cash flow | |||||
| Free cash flow margin | 42.5% | Good beats 97% | 16.3% | 32.1% | ▲ Better |
| Free cash flow growth, 3 years a year | +4.3% | Average beats 50% | +4.3% | – | – |
| Accruals (lower is better) | −34.0% | Good beats 99% | −3.9% | – | – |
| Efficiency | |||||
| Inventory turnover | 3.2x | Average beats 55% | 2.9x | 3.7x | ≈ In line |
| Days sales outstanding | 61 days | Average beats 56% | 62 days | 61 days | ≈ In line |
These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.
Fundamentals checklist
● 5 Good · ● 2 Average · ● 8 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldGood
Risk models
Altman Z''Bad
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Average
Revenue growth (3y)Bad
Growth consistencyAverage
Balance sheet
Current ratioBad
Interest coverBad
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 39/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Operating income | $9.9B | $7.3B | $7.6B | $1.7B | $10.0B |
| Net income | $6.2B | $4.6B | $5.7B | $480M | $8.5B |
| Operating cash flow | $11.4B | $9.1B | $8.0B | $10.8B | $10.0B |
| Operating margin | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Free cash flow | $10.8B | $8.3B | $7.4B | $10.3B | $9.5B |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 0 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 153.7 | Bullish |
| EMA 10 | 153.7 | Bullish |
| SMA 20 | 150.8 | Bullish |
| EMA 20 | 151.7 | Bullish |
| SMA 50 | 148.1 | Bullish |
| EMA 50 | 147.3 | Bullish |
| SMA 100 | 138.5 | Bullish |
| EMA 100 | 142.3 | Bullish |
| SMA 200 | 137.4 | Bullish |
| EMA 200 | 135.8 | Bullish |
Oscillators (daily)
| RSI (14) | 60.79 | Neutral |
| MACD (12, 26) | 2.44 | Bullish |
| Momentum (12) | 8.99 | Bullish |
| Stochastic %K (14) | 81.46 | Bearish |
| Williams %R (14) | -18.54 | Bearish |
| CCI (20) | 106.6 | Bearish |
Pivot points (classic, last session)
S3 149.9 | S2 151.5 | S1 154.3 | Pivot 155.9 | R1 158.7 | R2 160.3 | R3 163.2 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
3.25 USD
Yield on today's price
2.07%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 0.8200 | |
| 0.8200 | |
| 0.8200 | |
| 0.7900 | |
| 0.7900 | |
| 0.7900 | |
| 0.7900 | |
| 0.7700 | |
| 0.7700 | |
| 0.7700 | |
| 0.7700 | |
| 0.7500 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
ETFs that hold GILD
| ETF | Share of the fund |
|---|---|
| IBB iShares Biotechnology | 6.84% |
| XLV Health Care Select Sector SPDR | 2.73% |
| IYH iShares U.S. Healthcare | 2.66% |
| VHT Vanguard Health Care | 2.64% |
| FBT First Trust NYSE Arca Biotechnology In... | 2.45% |
| FHLC Fidelity MSCI Health Care Index | 2.34% |
| IXJ iShares Global Healthcare | 2.04% |
| COWZ Pacer US Cash Cows 100 | 1.93% |
The eight funds with the largest weight in GILD among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.
GILD stock splits
GILD has split its stock 5 times since 2001. The latest was a 2-for-1 split on 28 Jan 2013.
Full GILD stock split history →GILD SEC filings
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations
8-KSEC EDGAR
Entered a material agreement; Other events
424B5SEC EDGAR
424B5
424B5SEC EDGAR
424B5
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations
8-KSEC EDGAR
Shareholder vote results
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.